Tbo-filgrastim

(Granix®)

Tbo-filgrastim

Drug updated on 11/9/2023

Dosage FormInjection (subcutaneous; 300 mcg/ 0.5 mL, 480 mcg/ 0.8 mL)
Drug ClassLeukocyte growth factors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.